Gonzaga Silva Lúcio Flávio, Odorico de Moraes Manoel, Santos Dias Soares Felipe, Mota Moura Fé Daniel, Cavalcante João Luiz B G, Anselmo José Nilson N, Leitao Vasconcelos Paulo R
Department of Surgery, Federal University of Ceará, CEP 60.430-140, Rodolfo Teófilo, Fortaleza, Ceará, Brazil.
Nutrition. 2004 Feb;20(2):225-9. doi: 10.1016/j.nut.2003.12.001.
We evaluated the effects of l-arginine-enriched total enteral nutrition (LATEN) on tumor-free and right kidney tumor-bearing rats through the determination of in vivo concentrations of metabolites to better understand intermediary metabolism in this model.
Rats were individually housed in wire cages within a controlled environment (25 degrees C and 50% relative humidity) and exposed to a 12-h light-and-dark cycle. Rats comprised the following groups: tumor-free on enteral nutrition plus l-amino acid (n = 8); tumor-free on enteral nutrition plus l-arginine (n = 8); tumor bearing on enteral nutrition plus l-amino acids (n = 8); and tumor bearing on enteral nutrition plus l-arginine (n = 8). Rats had their right kidneys inoculated with saline or tumor cells and were subjected to laparotomy or gastrostomy on day 1 and received chow diet for the next 2 days. Gastrostomy with enteral nutrition was performed on days 3 to 9. On day 9, body weight gain, tumor growth as volume, in vivo blood (microM/mL), and tissue (microM/g) metabolite concentrations were determined. The Mann-Whitney U test was used to test significance.
LATEN in tumor-free rats decreased liver (0.25 +/- 0.03 versus 0.13 +/- 0.03 micromol/g, P < 0.05) and right kidney (0.13 +/- 0.1 versus 0.04 +/- 0.00 micromol/g, P < 0.05) ketone body concentrations. LATEN in tumor-bearing rats decreased blood pyruvate (0.17 +/- 0.01 versus 0.10 +/- 0.008 microM/mL, P < 0.005), lactate (5.2 +/- 0.3 versus 2.9 +/- 0.28 microM/mL, P < 0.01), and glucose (6.4 +/- 0.8 versus 3.7 +/- 0.5 microM/mL, P < 0.05). Glucose concentrations decreased in liver (13.9 +/- 2.0 versus 4.89 +/- 0.6 microM/g, P < 0.005) and tumor (3.5 +/- 0.8 versus 1.41 +/- 0.3 microM/g, P < 0.05). There were no changes in body weight gain (21 +/- 2.0 versus 30.3 +/- 3.6 g) or tumor growth (1.53 +/- 0.1 versus 1.26 +/- 0.01 cm(3)).
LATEN decreased ketone body concentrations in liver and kidney in tumor-free rats, possibly due to lower ketogenesis and decreased kidney uptake. In tumor-bearing rats, LATEN decreased lacticemia and glycemia and pyruvate blood concentrations. LATEN also reduced liver and tumor glucose concentrations in tumor-bearing animals. The possibility of LATEN-induced insulin and insulin-like growth factor-1 liberation signaling these changes is discussed.
通过测定体内代谢物浓度,评估富含L-精氨酸的全肠内营养(LATEN)对无肿瘤和右肾荷瘤大鼠的影响,以更好地了解该模型中的中间代谢。
将大鼠单独饲养在可控环境(25摄氏度和50%相对湿度)的铁丝笼中,暴露于12小时明暗循环。大鼠分为以下几组:接受肠内营养加L-氨基酸的无肿瘤大鼠(n = 8);接受肠内营养加L-精氨酸的无肿瘤大鼠(n = 8);接受肠内营养加L-氨基酸的荷瘤大鼠(n = 8);接受肠内营养加L-精氨酸的荷瘤大鼠(n = 8)。给大鼠右肾接种生理盐水或肿瘤细胞,并在第1天进行剖腹术或胃造口术,接下来2天给予常规饮食。在第3至9天进行胃造口术并给予肠内营养。在第9天,测定体重增加、肿瘤体积生长、体内血液(微摩尔/毫升)和组织(微摩尔/克)代谢物浓度。使用曼-惠特尼U检验来检验显著性。
无肿瘤大鼠中的LATEN降低了肝脏(0.25±0.03对0.13±0.03微摩尔/克,P < 0.05)和右肾(0.13±0.1对0.04±0.00微摩尔/克,P < 0.05)中的酮体浓度。荷瘤大鼠中的LATEN降低了血液丙酮酸(0.17±0.01对0.10±0.008微摩尔/毫升,P < 0.005)、乳酸(5.2±0.3对2.9±0.28微摩尔/毫升,P < 0.01)和葡萄糖(6.4±0.8对3.7±0.5微摩尔/毫升,P < 0.05)。肝脏(13.9±2.0对4.89±0.6微摩尔/克,P < 0.005)和肿瘤(3.5±0.8对1.41±0.3微摩尔/克,P < 0.05)中的葡萄糖浓度降低。体重增加(21±2.0对30.3±3.6克)或肿瘤生长(1.53±0.1对1.26±0.01立方厘米)没有变化。
LATEN降低了无肿瘤大鼠肝脏和肾脏中的酮体浓度,可能是由于较低的生酮作用和肾脏摄取减少。在荷瘤大鼠中,LATEN降低了血乳酸、血糖和丙酮酸血液浓度。LATEN还降低了荷瘤动物肝脏和肿瘤中的葡萄糖浓度。讨论了LATEN诱导胰岛素和胰岛素样生长因子-1释放引发这些变化的可能性。